Categories
I-CARE Early Covid (3)
I-CARE Flu and RSV (1)
I-PREVENT (28)
I-RECOVER Long Covid (3)
I-RECOVER Post-Vaccine (3)
MATH+ (20)
Tags
25-hydroxyvitamin D (2)
25‐HYDROXY VITAMIN D (2)
Ambulatory treatment (2)
Anti-inflammatory (2)
Anti-Inflammatory Agents (1)
Anticoagulant (2)
Antimicrobial Cationic Peptides (1)
Antiparasitic Agents (3)
Antiviral (2)
Ascorbic Acid (3)
Calcifediol (1)
Collagen (1)
Coronavirus (2)
COVID-19 (23)
Dithiothreitol (1)
Endothelial Barrier (1)
Endothelial Permeability (1)
Epidemiology (2)
Ergocalciferols (1)
Famotidine (7)
Fixed drug eruption (1)
Glucocorticosteroids (3)
Heparanase (2)
Human immunodeficiency virus (HIV) (1)
Hydroxychloroquine (2)
Inflammation (4)
ivermectin (18)
Melatonin (13)
Methylprednisol (2)
Nitric Oxide (1)
Omicron (6)
Onchocerciasis (1)
pharmacokinetics (1)
Pneumonia (2)
SARS-CoV-2 (20)
Sars-CoV2 (2)
Sepsis (3)
Septic (2)
Spike Protein (5)
Stevens–Johnson syndrome (SJS) (1)
Tempol (1)
viral infection (3)
Vitamin C (3)
Vitamin D (6)
vitamin D 2 (1)
Conclusions: The results of this case series suggest that high-dose oral famotidine is well tolerated and associated with improved patient-reported outcomes in non-hospitalised patients with COVID-19.
Categories: MATH+
Tags: COVID-19, Famotidine, PROMs, SARS-CoV-2
